Skip to main content
21 May | 2024

Outstanding participation of the BBRC in the Euro-PAD symposium

Last week, a new Euro-PAD symposium was held, a European working group involved in the EPAD and AMYPAD projects in which the Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, participates.

The event, held in Amsterdam on May 16 and 17, aimed to discuss the latest developments in the field of neuroimaging and Alzheimer's biomarkers, in addition to seeking new lines of research and funding.

The programming of this edition has included several interventions by BBRC research staff:

  • Mahnaz Shekari, who recently defended the fifth doctoral thesis developed at the BBRC, took part in the "PET quantification and analysis" section together with David Vállez, new Director of the center's Neuroimaging Platform. Vállez also talked about the new developments of the consortium during the last year. Shekari, for her part, has offered the talk "EARL's new Brain PET/CT accreditation - methodological aspects and validation in the AMYPAD consortium".
  • Paula Mera, scientific project manager of the BBRC's Research Management Office, has also contributed to the annual review of the consortium, with a review of the "Marie Curie Doctoral Network".
  • Researchers Raffaele Cacciaglia, Michalis Kassinopoulos and Irene Cumplido-Mayoral have participated in different sections on quantification and advanced analysis of magnetic resonance imaging techniques and Positron Emission Tomography (PET).
  • Finally, researchers Natàlia Vilor-Tejedor and Marc Suárez-Calvet have offered the presentations "Imaging genetics in AD beyond APOE" and "Plasma biomarkers combinations to detect amyloid accumulators in preclinical Alzheimer's disease", respectively.


More information

EPAD (European Prevention of Alzheimer's Dementia Consortium), funded by the Innovative Medicines Initiative (IMI), was an interdisciplinary research program with the participation of 39 European organizations to optimize the testing and development of preventive treatments for Alzheimer's.

AMYPAD (Amyloid Imaging to Prevent Alzheimer’s Disease), funded by the Horizon 2020 research and innovation program of the European Union, has been a European collaboration with 17 institutions involved to improve knowledge, diagnosis and treatment of Alzheimer's through the use of a brain positron emission tomography (PET).